Jordan Croteau has 15+ years of digital systems design and implementation experience in biopharmaceutical manufacturing operations, process development, and facilities. Prior to Moderna, Jordan was responsible for developing the new technology introduction and technology readiness processes at Kite Pharma. Previously, he served as MES lead in the Global Automation Center of Excellence at Biogen, Inc. In this role, Jordan led the global execution system design and its integration with Biogen’s manufacturing and enterprise systems. He is currently a member of ISA and has been an active contributor to ISA 95. Jordan received a BS in Chemical Engineering from Worcester Polytechnic Institute.

Experienced Manufacturing Operations strategist, with a demonstrated history of implementing in the biotechnology industry. Skilled in Enterprise-Control System Integration (ISA 95), MES, Materials Management, Product Lifecycle Management, Process Control, and Oracle ERP.

At B. Braun Melsungen responsible for the SAP ERP and MES support functions; including Master Data maintenance, End User training, Master Batch Record enhancements, MES configuration, and writing and executing test scripts for system validation.

Jerry Gonzalez is a Professional Engineer with experience in the pharmaceutical industry, manufacturing Large-volume Parenterals and Medical Devices. He has held positions in Engineering, Manufacturing, Planning, Scheduling, and SPC training. Jerry is currently the Business Systems Manager at B Braun Medical, Inc. in Irvine, CA, where he is responsible for the functional support of the ERP system (SAP) and the MES-EBR system used for the manufacturing of IV Solutions, as well as the Master Scheduling functions. He has spoken at various MES conferences and symposiums in the United States, Singapore, Germany, Austria and France. Jerry holds an MBA degree, with a concentration in Supply Chain Management, from the University of La Verne. As a volunteer, Jerry was president of the APICS Orange County chapter, and District Manager of the APICS Southwest District. Jerry teaches an Operations Planning and Inventory Control course at California State University, Fullerton as a member of its adjunct faculty.

30+ years experience in IT and OT for Pharmaceutical and Chemical industry.

Graduated from French University with a Masters Degree in computer science. 15 years experience in headquarters of Chemical/Pharmaceutical companies in Basel-Switzerland, in diverse leading positions with increased responsibilities covering successively IT Infrastructure, Supply Chain Systems, IT Project management and IT Project Management/Portfolio Management methodologies. Moved to Singapore in 2005 for leading the implementation of IT Systems for the a new greenfield Pharmaceutical tableting plant project, and subsequently took responsibility of the design of IT Infrastructure and Systems for a new large Pharma Biotech manufacturing facility.

Transferred to Lonza Singapore in 2009 to lead the implementation of all IT Infrastructure and Systems required to run a new large scale multi product Pharma Biological Custom Manufacturing facility. Took subsequently the lead of IT for Lonza Singapore, India and Japan. Moved then for 2 years to a global role in IT Innovation. Since 2019, head of APAC Operational Technology for LONZA.

Under the umbrella of PHARMA 4.0, Initiating brand new country largest pharmaceutical project in 40 acres of land with the value of 400 millions USD investment scope of different portfolio and dosage forms targeting local and US FDA Market ensuring data integrity, productivity and green factory by design.

After studying electrical engineering Martin Fuseks career started as a project engineer and later as a project manager and quality manager for MES at Propack Data GmbH. In 2005, he moved from the vendor to customer site and hold various IT management positions within Merckle Biotech and later in the Novartis group. In 2019 he took the role of Global Program Manager Manufacturing at Merck KGaA, before he joined Roche in 2021 as Head of Manufacturing IT.

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, PA and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We focus on enabling treatments that prevent illness and support healthier lifestyles. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers. We provide a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Our scale and resources mean we can provide a one-stop solution for our customers to help people get well, feel well, and stay well..

Healthcare Pharmaceuticals Ltd. is one of the leading pharmaceutical company in Bangladesh having certified by the international pharmaceutical regulatory authorities like TGA (Australia), NPRA (Malaysia), MCAZ (Zimbabwe), TFDA (Tanzania) etc. HPL is focused on innovation and provides healthcare solutions that improves and extends people’s lives. From prevention to treatment, HPL transforms scientific innovation into healthcare solutions in Antihistamine, Antiemetic, Anti-diabetic, Analgesic or Antipyretic, Anti-infective, Bone Care, Biotech and Oncology, CNS Drug, Cardiovascular, Dermatological Products, Respiratory Care, Ophthalmic, Vitamin & Mineral and many other areas. Healthcare started its journey in 1988 by establishing a company named Healthcare Distribution Limited in association with Roche Limited, a Switzerland based renowned multinational company. Until 2001 HPL was responsible for importing and distributing Roche products to the local market. In 1996 HPL decided to establish its own pharmaceutical plant to produce the products those are imported from Roche, Switzerland and other local generics for indigenous market. Now Healthcare is the fastest growing organization in the pharmaceutical industry of Bangladesh. We are now producing more than two hundred products with various types of dosage forms which includes Tablets, Capsules, Liquids, Dry syrups, Creams & Ointments, Gels, Small Volume Parenteral, and Eye Drops covering almost all therapeutic classes. There are also numerous products in the launching pipeline for local and overseas markets in Asia, Africa and CIS region.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.